Evidence map›Paper›PMID 40073277›Full record

SynthesisPain medicine (Malden, Mass.)2025

Platelet-rich plasma injections as a second-line treatment in patients with tendinopathy-related chronic pain and failure of conservative treatment: a systematic review and meta-analysis.

Mathieu Nadeau-Vallée, Sami Ellassraoui, Véronique Brulotte

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Pain medicine (Malden, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mathieu Nadeau-ValléeDepartment of Anesthesiology and Pain Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.ORCID 0000-0003-2397-5495
Sami EllassraouiDepartment of Anesthesiology and Pain Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.
Véronique BrulotteDepartment of Anesthesiology and Pain Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada.

Funding

Dr Véronique Brulotte
6 · The paper itself

Abstract

designPlatelet-rich plasma (PRP) is a popular treatment option in managing chronic tendinopathies, although the literature is inconsistent, mainly because of significant heterogeneity in patient populations. Patients who failed conservative management may respond differently than those who have not undergone first-line treatment. This systematic review and meta-analysis aimed to evaluate the efficacy of PRP injections in reducing pain and improving function in patients with chronic tendinopathy who failed conservative treatment. A comprehensive search of Medline, Embase, Cochrane Library, CINAHL Complete and Dissertations & Theses Global was conducted to identify randomized controlled trials (RCTs) comparing the effect of PRP vs non-surgical treatments on pain and functional outcomes in adult non-responders to conservative management.

resultsA total of 9 RCTs involving 488 patients were included in the review. Of those, 6 studies at low risk of bias were included in the meta-analysis. PRP significantly reduced pain at both 6 and 12 months compared to control treatments (mean difference: -0.83 [95% confidence intervals (CI): -1.61 to -0.04] at 6 months; and -1.11 [95% CI: -2.10 to -0.12] at 12 months). This effect was also seen at 24 months, although based on limited data. Subgroup analysis revealed no significant differences in pain reduction between upper and lower limb tendinopathies. Functional improvement was observed in some studies, though the heterogeneity in outcome measures precluded a pooled analysis. Heterogeneity was substantial across studies, likely due to differences in PRP preparation, site of tendinopathy, and study methodologies.

conclusionDespite these limitations, the findings suggest that PRP reduces pain in patients suffering from chronic tendinopathy who have not responded to first-line therapies. Further high-quality research with standardized protocols and longer follow-up is necessary to confirm PRP's long-term efficacy and safety.

Indexed as

Chronic PainConservative TreatmentPlatelet-Rich PlasmaTendinopathyHumansRandomized Controlled Trials as Topicchronic painplatelet-rich plasmaPRPtendinopathytreatment

Identifiers

PMID40073277
PMCPMC12230405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.